The changes of serum soluble HLA-class I and CD8 concentrations during interferon treatment of chronic hepatitis C patients

International Hepatology Communications

Volumn 6, Issue 6, 1997, Pages 316-323

  Hagihara, Masao ^a   Shimura, Tatsuo ^b   Takebe, Kentaro ^b   Munkhbat, Batmunkh ^a   Yamamoto, Kozue ^c   Hosoi, Katsumi ^a   Kagawa, Tatehiro ^a   Watanabe, Norihito ^a   Matsuzaki, Shohei ^a   Tsuji, Kimiyoshi ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b GUNMA UNIVERSITY   (Japan)

^c TOKAI UNIVERSITY HOSPITAL   (Japan)

Author keywords

chronic hepatitis; interferon; soluble CD8; soluble HLA I

Indexed keywords

ALPHA INTERFERON; CD8 ANTIGEN; HLA ANTIGEN CLASS 1;

ARTICLE; BLOOD ANALYSIS; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS C; HUMAN; IMMUNE RESPONSE; PRIORITY JOURNAL;

EID: 0031104724     PISSN: 09284346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-4346(97)00363-0     Document Type: Article

References (19)

1. [1] Stevenson FK, George AJT, Walters MT, Hamblin TJ. Analysis of soluble HLA-class I antigenic material in patients with immunological disease using monoclonal antibodies. J Immunol 1986; 86: 187-90.
2. [2] Hagihara M, Shimura T, Tsuji K et al. Clinical significance of serum soluble HLA-class I antigens in systemic lupus erythematosus. Tokai J Exp Clin Med 1993; 18: 61-64.
3. [3] Puppo F, Pellicci R, Brenci S et al. HLA-class I soluble antigen serum levels in liver transplantation: A predictor marker of acute rejection. Human Immunol 1994; 40: 166-170.
4. [4] Wijngaard PW, Van der Meulen, Meyling FHIG, de Jonge N, Schuurman HJ. Soluble CD8 and CD25 in serum of patients after heart transplantation. Clin Exp Immunol 1994; 97: 505-509.
5. [5] Linker-Israeli M, Hyun S, Ozeri-Chen, Ozeri-Chen Tal, Wallace DJ, Banks K, Klinenberg JR. Elevated in vivo and in vitro secretion of CD8 molecules in patients with systemic lupus erythematosus. J Immunol 1994; 152: 3158-3367. (gammaglobulin replacement therapy. Lancet 1987; 1: 539-541.)
6. [5] Linker-Israeli M, Hyun S, Ozeri-Chen, Ozeri-Chen Tal, Wallace DJ, Banks K, Klinenberg JR. Elevated in vivo and in vitro secretion of CD8 molecules in patients with systemic lupus erythematosus. J Immunol 1994; 152: 3158-3367. (gammaglobulin replacement therapy. Lancet 1987; 1: 539-541.)
7. [6] Végh Z, Wang P, Kein E. Klein E. Increased expression of MHC class I molecules on human cells after short time IFN-gamma treatment. Mol Immunol 1993; 30: 849-854.
8. [7] Paul RG, Roodman ST, Campbell CR et al. HLA-class I antigen expression as a measure of response to antiviral therapy of chronic hepatitis B. Hepatology 1991; 13: 820-825.
9. [8] Hayata T, Nakano Y, Yoshizawa K, Sodeyama T, Kiyosawa K. Effects of interferon on intrahepatic human leukocyte antigens and lymphocyte subsets in patients with chronic hepatitis B and C. Hepatology 1991; 13: 1022-1028.
10. [9] Li X, Jeffers LJ, Reddy R et al. Immunophenotyping of lymphocytes in liver tissue of patients with chronic liver diseases by flow cytometry. Hepatology 1991; 14: 121-127.
11. [10] Brieva JA, Villar LM, Leoro G, Alvarez-Cermeno JC, Roldan E, Gonzalez-Porque P. Soluble HLA-class I antigen secretion by normal lymphocytes: relationship with cell activation and effect of interferon-gamma. Clin Exp Immunol 1990; 82: 390-395.
12. [11] He X, Le J. Alternative splicing of HLA-class I transcripts induced by IFN-gamma and TNF in fibroblasts: release of soluble HLA-class I heavy chain and associate protein. Cell Immunol 1995; 162: 159-168.
13. [12] Aulitzky WE, Grosse-Wilde H, Westhoff U, Tilg H, Aulitzky W, Gastl G. Enhanced serum levels of soluble HLA-class 1 molecules are induced by treatment with recombinant interferon-gamma. Clin Exp Immunol 1991; 86: 236-239.
14. [13] Hillebrand K, Moritz T, Westhoff U, Niederle N, Grosse-Wilde H. Soluble HLA-class I and beta-2-microglobulin plasma concentrations during interferon treatment of chronic myelogeneous leukemia. Vox Sang 1994; 67: 310-314.
15. [14] Quiroga JA, Martin J, Pardo M, Carrefio. Serum levels of soluble immune factors and pathogenesis of chronic hepatitis C, and their relation to therapeutic responses to interferon-alpha. Dig Dis Sci 1994; 39: 2485-2496.
16. [15] Everett ET, Scomik JC, Davis G, Kao KJ. Induction of erythrocyte HLA expression during interferon treatment and HIV infection. Hum Immunol 1990; 29: 14-22.
17. [16] Puppo F, Picciotto A, Brenci S, et al. Behavior of soluble HLA-class I antigens in patients with chronic hepatitis C during interferon therapy: an early predictor marker of response? J Clin Immunol 1995; 15: 179-184.
18. [17] Pfeffel F, Pindlich J, Petermann, Müller C. Soluble CD8 and CD4 antigens in viral hepatitis and alcoholic cirrhosis. J Hepatol 1994; 20: 245-251.
19. [18] Ferrone S, Yamamura M, Grosse-Wilde H et al. Summary of serum-soluble HLA-class I antigen component. In: HLA 1991, Proceedings 11th International Histocompatibility Workshop Conference. Oxford: Oxford Science Publications, 1992; 1057-1061.